A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CRIS SEC filings page.
Curis Inc (CRIS) reported $9.4M in revenue for fiscal year 2025, down 13.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Expense cuts sharply narrowed reported losses, but cash consumption remains much larger and near-term liquidity is tight.
FY2025 operating cash flow was-$27.2M against a net loss of$7.6M , exposing a cash-conversion gap: operations consumed far more cash than the income statement loss alone suggests. Even as operating margin improved from-408.3% to-60.5% , the gap shows that accounting improvement had not yet translated into comparable cash economics.
The FY2025 loss reduction came with a smaller revenue base: revenue fell
Current assets of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Curis Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Curis Inc held $5.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $27.2M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Curis Inc scores 10/100 among other emerging companies.
Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Curis Inc scores 10/100 on it among other emerging companies.
Curis Inc spent $28.3M on research and development in fiscal year 2025, which was 186.4% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Curis Inc scores 100/100 among other emerging companies.
Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Curis Inc scores 39/100 on it among other emerging companies.
Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Curis Inc scores 64/100 on it among other emerging companies.
Curis Inc's cash, cash equivalents and investments came to $5.1M at the end of fiscal year 2025, against $14.5M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Curis Inc scores 37/100 among other emerging companies.
Curis Inc scores -88.20, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $1.2B against total assets of $20.0M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Curis Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) passes.
Curis Inc reported a net loss of $7.6M while operations used $27.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Curis Inc reported a net loss of $8.1M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Not reported for Q3 2026.
Cash & Balance Sheet
Curis Inc held $5.0M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Curis Inc's quarterly ROE was -318.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. Against the prior quarter it is down 135.5 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
Curis Inc invested $5.6M in research and development in Q3 2026. This represents a decrease of 13.0% from the same quarter a year earlier. Against the prior quarter it is down 16.7%.
Not reported for Q3 2026.
Not reported for Q3 2026.
CRIS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0-100.0% | $0-100.0% | $1.1M-66.0% | $3.2M+8.4% | $2.7M+8.0% | $2.4M+14.1% | $3.3M+24.1% |
| R&D Expenses | $5.6M-13.0% | $6.7M-10.0% | $6.4M-24.5% | $5.8M-35.0% | $6.4M-33.8% | $7.5M-27.3% | $8.5M-11.2% | $9.0M-10.0% |
| SG&A Expenses | $3.2M-13.7% | $3.2M-8.5% | $5.1M+27.3% | $2.9M-14.0% | $3.7M-2.7% | $3.5M-26.4% | $4.0M-18.5% | $3.4M-31.2% |
| Operating Income | -$8.7Mn/m | -$9.9Mn/m | -$11.5Mn/m | $19.6Mn/m | -$6.9Mn/m | -$8.3Mn/m | -$10.2Mn/m | -$9.0Mn/m |
| EBITDA | N/A | -$9.9Mn/m | -$11.5Mn/m | $19.7Mn/m | -$6.9Mn/m | -$8.2Mn/m | -$10.1Mn/m | -$9.0Mn/m |
| Net Income | -$8.1Mn/m | -$8.6Mn/m | -$24.2Mn/m | $19.4Mn/m | -$7.7Mn/m | -$8.6Mn/m | -$10.6Mn/m | -$9.6Mn/m |
| EPS (Basic) | -$1.94 | -$4.02 | -$25.00 | N/A | -$9.86 | -$13.61 | -$25.00n/m | -$22.20n/m |
| EPS (Diluted) | -$1.94 | -$4.02 | -$25.00 | N/A | -$9.86 | -$13.61 | -$25.00n/m | -$22.20n/m |
| Diluted Shares (Avg) | 4M | 2M | 968,174 | N/A | 784,109 | 631,475 | 424,694+46.9% | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
CRIS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $18.8M-32.0% | $19.0M-35.1% | $29.7M-24.5% | $20.0M-51.6% | $27.6M-34.9% | $29.2M-42.0% | $39.3M-36.6% | $41.3M-46.6% |
| Current Assets | $6.9M-50.3% | $6.7M-53.4% | $16.6M-33.0% | $6.9M-73.8% | $13.9M-48.4% | $14.4M-58.2% | $24.8M-46.1% | $26.4M-56.7% |
| Cash & Equivalents | $5.0M-44.6% | $5.1M-50.0% | $15.0M-26.0% | $5.1M-74.7% | $9.1M-56.6% | $10.1M+1.4% | $20.3M-32.3% | $20.0M-25.1% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0-100.0% |
| Accounts Receivable | N/A | N/A | N/A | $0-100.0% | $3.2M+8.9% | $2.8M+8.1% | $2.3M+7.5% | $3.3M+19.9% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $9.0M0.0% | $9.0M0.0% | $9.0M0.0% | $9.0M0.0% | $9.0M0.0% | $9.0M0.0% | $9.0M0.0% | $9.0M0.0% |
| Total Liabilities | $16.2M-61.6% | $14.3M-67.0% | $17.0M-63.0% | $14.5M-69.3% | $42.3M-17.3% | $43.2M-15.4% | $45.9M-12.6% | $47.3M-18.0% |
| Current Liabilities | $16.2M-18.4% | $13.7M-29.4% | $15.0M-25.6% | $14.1M-26.0% | $19.9M-9.6% | $19.4M0.0% | $20.1M+78.0% | $19.0M-13.6% |
| Non-Current Liabilities | $0-100.0% | $600K-97.5% | $2.0M-92.2% | $428K-98.5% | $22.4M-23.2% | $23.8M-24.9% | $25.8M-37.4% | $28.2M-20.7% |
| Total Equity | $2.6Mn/m | $4.7Mn/m | $12.7Mn/m | $5.5Mn/m | -$14.7Mn/m | -$14.0Mn/m | -$6.6M-169.8% | -$6.0M-130.5% |
| Retained Earnings | -$1.3Bn/m | -$1.3Bn/m | -$1.3Bn/m | -$1.2Bn/m | -$1.3Bn/m | -$1.3Bn/m | -$1.3Bn/m | -$1.2Bn/m |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
CRIS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.7Mn/m | -$9.6Mn/m | -$9.0Mn/m | -$6.4Mn/m | -$5.6Mn/m | -$8.0Mn/m | -$7.3Mn/m | -$9.3Mn/m |
| Depreciation & Amortization | N/A | $8K-81.0% | $8K-86.4% | $36K+125.0% | $32K-47.5% | $42K-32.3% | $59K-7.8% | $16K-75.0% |
| Stock-Based Compensation | $526K-43.1% | $569K-49.9% | $575K-50.6% | N/A | $924K-33.2% | $1.1M-33.4% | $1.2M-25.3% | N/A |
| Investing Cash Flow | N/A | $0n/m | $0n/m | $2.5Mn/m | $0-100.0% | $0n/m | $0-100.0% | -$428K-102.9% |
| Financing Cash Flow | $5.7M+27.0% | -$282Kn/m | $18.9M+151.3% | -$119K-101.3% | $4.5Mn/m | -$2.1Mn/m | $7.5Mn/m | $8.8Mn/m |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
CRIS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | 1724.0% | -218.0% | -300.1% | -426.8% | -268.9% |
| Net Margin | N/A | N/A | N/A | 1700.9% | -243.4% | -312.6% | -446.0% | -287.5% |
| Return on Equity | -318.3% | -182.8% | -190.4% | 354.4% | N/A | N/A | N/A | N/A |
| Return on Assets | -43.2%-15.2pp | -45.2%-15.8pp | -81.5%-54.5pp | 96.9%+120.3pp | -28.0%-4.2pp | -29.4%-6.0pp | -27.0%-7.8pp | -23.3%-8.2pp |
| Current Ratio | 0.43-0.3x | 0.49-0.3x | 1.11-0.1x | 0.49-0.9x | 0.70-0.5x | 0.74-1.0x | 1.23-2.8x | 1.39-1.4x |
| Liabilities-to-Equity | 6.37 | 3.04 | 1.34 | 2.66 | N/A | N/A | N/A | N/A |
| Asset Turnover | N/A | 0.00-0.1x | 0.00-0.1x | 0.060.0x | 0.110.0x | 0.090.0x | 0.060.0x | 0.080.0x |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: The current ratio is below 1.0 (0.49), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Curis Inc CRIS | FY2025 | $9.4M | -$7.6M | -80.3% | $4.1M | 43/100 |
| Can-Fite BioPharma Ltd. CANF | FY2025 | $405K | -$9.8M | N/A | $4.4M | — |
| AIM ImmunoTech Inc. AIM | FY2025 | $88K | -$14.0M | N/A | $4.6M | — |
| Processa Pharmaceuticals, Inc. PCSA | FY2025 | N/A | -$13.6M | N/A | $4.4M | — |
| Lantern Pharma Inc. LTRN | FY2025 | N/A | -$17.1M | N/A | $3.9M | — |
| Alzamend Neuro, Inc. ALZN | FY2026 | N/A | -$8.8M | N/A | $3.7M | — |
Where Curis Inc Ranks
Frequently Asked Questions
Curis Inc (CRIS) reported $9.4M in total revenue for fiscal year 2025. This represents a -13.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Curis Inc (CRIS) revenue declined by 13.4% year-over-year, from $10.9M to $9.4M in fiscal year 2025.
No, Curis Inc (CRIS) reported a net loss of $7.6M in fiscal year 2025, with a net profit margin of -80.3%.
Curis Inc (CRIS) had EBITDA of -$5.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Curis Inc (CRIS) had an operating margin of -60.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Curis Inc (CRIS) had a net profit margin of -80.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Curis Inc (CRIS) has a return on equity of -138.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Curis Inc (CRIS) recorded an outflow of $27.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Curis Inc (CRIS) had $20.0M in total assets as of fiscal year 2025, including both current and long-term assets.
Curis Inc (CRIS) invested $28.3M in research and development during fiscal year 2025.
Curis Inc (CRIS) had a current ratio of 0.49 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Curis Inc (CRIS) had a liabilities-to-equity ratio of 2.66 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Curis Inc (CRIS) had a return on assets of -38.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Curis Inc (CRIS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $4.1M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Curis Inc (CRIS) trades at 0.4x sales, its market capitalization divided by $9.4M revenue, FY2025. The market capitalization is $4.1M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Curis Inc (CRIS) held $5.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $27.2M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Curis Inc (CRIS) has an Altman Z-Score of -88.20, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Curis Inc (CRIS) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Curis Inc (CRIS) reported a net loss of $7.6M while operations used $27.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Curis Inc (CRIS) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.